Dehydroascorbate-derivatized chitosan particles for targeting antimalarial agents to infected erythrocytes

Sofi, Hasham S.; Reddy, D.V. Siva; Khan, Tabassum; Ranjan, Rajeev; Srivastava, Ashish; Vaishya, Suniti; Sharma, Tanuj; Siddiqui, Mohammad Imran; Habib, Saman; Misra, Amit

doi:10.1016/j.ijpharm.2017.03.088

Cited by 14 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DHA's strategic competition for glucose uptake facilitated drug delivery to the cells, leading to a profound inhibition of parasite growth at an astonishingly low 1 nM concentration, dwarfing the effects of free chloroquine, which required a far higher 100 nM concentration to produce similar results. 111 Liposomal formulations, including PEGylated liposomes, have been investigated for delivering antimalarial drugs such as maduramicin, chloroquine, artemisinin, and dihydroartemisinin. 115−118 In an in vivo study, a comparison between PEGylated and liposome-encapsulated artemisinin, administered both alone and in combination with curcumin, yielded remarkable results.…”

Section: Employment Of Nanotechnology In Parasitic Diseasesmentioning

confidence: 99%

“…Various nanoparticle platforms, including liposomes, immunoliposomes, chitosan-based nanoparticles, peptide-associated liposomes, and solid lipid nanoparticles, have been explored for their ability to deliver drugs to infected red blood cells, enhancing drug efficacy and combating drug resistance. These nanoparticles not only were able to deliver drug at a specific site which reduces the required doses but also can help fight efflux-associated drug resistance. ,,,, An ingenious chloroquine formulation, rooted in chitosan and infused with dehydroascorbic acid (DHA), exhibited a remarkable surge in the level of drug uptake by infected red blood cells (iRBCs). DHA’s strategic competition for glucose uptake facilitated drug delivery to the cells, leading to a profound inhibition of parasite growth at an astonishingly low 1 nM concentration, dwarfing the effects of free chloroquine, which required a far higher 100 nM concentration to produce similar results .…”

Section: Employment Of Nanotechnology In Parasitic Diseasesmentioning

confidence: 99%

“…These nanoparticles not only were able to deliver drug at a specific site which reduces the required doses but also can help fight efflux-associated drug resistance. ,,,, An ingenious chloroquine formulation, rooted in chitosan and infused with dehydroascorbic acid (DHA), exhibited a remarkable surge in the level of drug uptake by infected red blood cells (iRBCs). DHA’s strategic competition for glucose uptake facilitated drug delivery to the cells, leading to a profound inhibition of parasite growth at an astonishingly low 1 nM concentration, dwarfing the effects of free chloroquine, which required a far higher 100 nM concentration to produce similar results . Liposomal formulations, including PEGylated liposomes, have been investigated for delivering antimalarial drugs such as maduramicin, chloroquine, artemisinin, and dihydroartemisinin. − In an in vivo study, a comparison between PEGylated and liposome-encapsulated artemisinin, administered both alone and in combination with curcumin, yielded remarkable results.…”

Section: Employment Of Nanotechnology In Parasitic Diseasesmentioning

confidence: 99%

See 2 more Smart Citations

Nanotechnology-Based Strategies in Parasitic Disease Management: From Prevention to Diagnosis and Treatment

Tiwari,

Gupta,

Singh

et al. 2023

ACS Omega

View full text Add to dashboard Cite

Parasitic infections are a major global health issue causing significant mortality and morbidity. Despite substantial advances in the diagnostics and treatment of these diseases, the currently available options fall far short of expectations. From diagnosis and treatment to prevention and control, nanotechnology-based techniques show promise as an alternative approach. Nanoparticles can be designed with specific properties to target parasites and deliver antiparasitic medications and vaccines. Nanoparticles such as liposomes, nanosuspensions, polymer-based nanoparticles, and solid lipid nanoparticles have been shown to overcome limitations such as limited bioavailability, poor cellular permeability, nonspecific distribution, and rapid drug elimination from the body. These nanoparticles also serve as nanobiosensors for the early detection and treatment of these diseases. This review aims to summarize the potential applications of nanoparticles in the prevention, diagnosis, and treatment of parasitic diseases such as leishmaniasis, malaria, and trypanosomiasis. It also discusses the advantages and disadvantages of these applications and their market values and highlights the need for further research in this field.

show abstract

Section: Employment Of Nanotechnology In Parasitic Diseasesmentioning

confidence: 99%

Section: Employment Of Nanotechnology In Parasitic Diseasesmentioning

confidence: 99%

Section: Employment Of Nanotechnology In Parasitic Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Nanotechnology-Based Strategies in Parasitic Disease Management: From Prevention to Diagnosis and Treatment

Tiwari,

Gupta,

Singh

et al. 2023

ACS Omega

View full text Add to dashboard Cite

show abstract

“…Parasite inhibition was achieved at 1 nM concentration, while free drug exhibited a comparative activity at 100 nM. It is convincing that specific targeting can reduce the dose and overcome the efflux-based drug resistance [22]. Table 2 summarizes some of the antimalarial formulations which are based on active drug targeting mechanism.…”

Section: Active Drug Targetingmentioning

confidence: 99%

Nanobiotechnological modules as molecular target tracker for the treatment and prevention of malaria: options and opportunity

Jain

Vishwakarma

Gautam

et al. 2020

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Malaria is one of the major infectious diseases that remains a constant challenge to human being mainly due to the emergence of drug-resistant strains of parasite and also the availability of drugs, which are non-specific for their pharmacodynamic activity and known to be associated with multiple side effects. The disease has acquired endemic proportions in tropical countries where the hygienic conditions are not satisfactory while the environmental conditions favor the proliferation of parasite and its transmission, particularly through the female anopheles. It is obvious that to square up the problems, there is a need for designing and development of more effective drugs, which can combat the drug-resistant strains of the parasite. Molecular biology of the parasite and its homing into host cellular tropics provide multiple drug targets that could judiciously be considered for engineering and designing of new generation antimalarial drugs and also drug delivery systems. Though the recent reports document that against malaria parasite the vaccine could be developed, nevertheless, due to smart mutational change overs by the parasite, it is able to bypass the immune surveillance. The developed vaccine therefore failed to assure absolute protection against the malarial infection. In the conventional mode of treatment antimalarial drugs, the dose and dosage regimen that is followed at large crops up the contraindicative manifestations, and hence compromising the effective treatment. The emerging trends and new updates in contemporary biological sciences, material sciences, and drug delivery domain have enabled us with the availability of a multitude of mode and modules which could plunge upon the nanotechnology in particular to treat this challenging infection. The nanotechnology-based option may be tuned or customized as per the requirements to mark and target i.e. the infected RBCs, for targeted drug delivery.

show abstract

“…Chloroquine phosphate is mainly used in the treatment of malaria and rheumatism in clinical [81][82][83]. Numerous studies have presented that it has broad-spectrum antiviral effect [84].…”

Section: Chloroquine Phosphatementioning

confidence: 99%

COVID-19 Drug Treatment in China

et al. 2020

View full text Add to dashboard Cite

Purpose of Review An unprecedented outbreak of the novel coronavirus in China (COVID-19) occurred in December 2019, and then engulfed the entire world, presenting a significant and urgent threat to global health. Many research institutes have been involved in the development of drugs and vaccines against COVID-19. Recent Findings At present, the strategy of new use of old drugs is mainly used to screen candidate drugs against the novel coronavirus (later termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) and inhibit excessive immune response. Related research has made great progress. Summary In this review, we summarize the drugs used for COVID-19 treatment in China based on the emerging basic and clinical data. It is hoped that this review will be useful to provide guidance for the prevention, treatment, and control of COVID-19.

show abstract

Dehydroascorbate-derivatized chitosan particles for targeting antimalarial agents to infected erythrocytes

Cited by 14 publications

References 27 publications

Nanotechnology-Based Strategies in Parasitic Disease Management: From Prevention to Diagnosis and Treatment

Nanotechnology-Based Strategies in Parasitic Disease Management: From Prevention to Diagnosis and Treatment

Nanobiotechnological modules as molecular target tracker for the treatment and prevention of malaria: options and opportunity

COVID-19 Drug Treatment in China

Contact Info

Product

Resources

About